Government Website icon

The .gov means it's official.
A .gov website belongs to an official government organization in the United States.

Padlock icon

The site is secure.
The https:// or lock icon ensures you're safely connected to the website and any information you provide is encrypted.

Publications iconKansas Register

Volume 42 - Issue 27 - July 6, 2023

State of Kansas

Board of Pharmacy

Notice of Hearing on Proposed Administrative Regulation

A public hearing will be conducted at 8:30 a.m. Thursday, September 28, 2023, at the Office of Administrative Hearings, 1020 S. Kansas Ave., Topeka, Kansas, to review and consider the adoption of a proposed permanent regulation of the Kansas State Board of Pharmacy.

This 60-day notice of the public hearing shall constitute a public comment period for the purpose of receiving written public comments on the proposed regulation. All interested parties may submit written comments prior to the public hearing to Alexandra Blasi, Executive Secretary, 800 SW Jackson, Suite 1414, Topeka, KS 66612-1244, or by email to All interested parties will be given a reasonable opportunity to present their views orally regarding the adoption of the proposed regulation during the public hearing. In order to provide all parties an opportunity to present their views, it may be necessary to request that each participant limit any oral presentation to five minutes.

Any individual with a disability may request an accommodation in order to participate in the public hearing and may request the regulation and economic impact statement in an accessible format. Requests for accommodation to participate in the public hearing should be made at least 10 business days in advance of the hearing by contacting Alexandra Blasi, Executive Secretary, 800 SW Jackson, Suite 1414, Topeka, KS 66612-1244 or by phone at 785-296-4056. Handicapped parking is located at the north entrance to the building. Curbs at the north entrance are accessible to individuals with disabilities.

A summary of the proposed regulation and its economic impact follow. Copies of the regulation and economic impact statement may be viewed at (Note: Statements indicating that “The Board anticipates that the proposed new regulation will have minor to no economic impact” are intended to indicate that no economic impact on the Board, other state agencies, state employees, or the general public have been identified.)

K.A.R. 68-20-32. 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine included in schedule I. Pursuant to the Board’s emergency scheduling authority, the proposed permanent regulation would place flubromazolam in schedule I of the Kansas Uniform Controlled Substances Act until July 1, 2024, giving the Kansas legislature sufficient time to consider the drug for permanent scheduling. This schedule is reserved for drugs that have no known medicinal use. Any economic impact would be related to prosecution of alleged criminals for possession or sale of flubromazolam and any resultant conviction.

Alexandra Blasi
Executive Secretary
Board of Pharmacy

Doc. No. 051285